Michael E. Egger

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Jason Chesney, Karl D. Lewis, Harriet M. Kluger et al. · Journal for ImmunoTherapy of Cancer · 2022 · 320 citations · Full text

Life Sciences, Immunology, Oncology +17

Melanoma cell–derived exosomes promote epithelial–mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment

Deyi Xiao, Samantha N. Barry, Daniel Kmetz et al. · Cancer Letters · 2016 · 179 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the <i>p</i>-Glycoprotein (ABCB1) Modulator Tariquidar

Matthias Kühnle, Michael E. Egger, Christine Müller et al. · Journal of Medicinal Chemistry · 2009 · 154 citations · Full text

Medicine, Oncology, Pharmacology +15

Role of retroviral restriction factors in the interferon-α–mediated suppression of HIV-1 in vivo

Satish K. Pillai, Mohamed Abdel‐Mohsen, John Guatelli et al. · Proceedings of the National Academy of Sciences · 2012 · 118 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17

Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma

Jordan M. Cloyd, Huamin Wang, Michael E. Egger et al. · JAMA Surgery · 2017 · 115 citations · Full text

Medicine, Oncology, Surgery +17